ColoPrint diagnostic data

Researchers from Technische Universitat Munchen showed that in tumor tissue samples from 137 patients who underwent curative resection for stage II colorectal cancer, ColoPrint was the only parameter to significantly predict the development of distant metastasis (p=0.007). In patients identified as low-risk and high-risk by ColoPrint, the respective 5-year distant-metastasis-free survival (DMFS) rates were 95% and 79.9%. Identifying patients' risk using clinical parameters recommended by the American Society of Clinical Oncology was not significantly associated with predicting the development of distant metastasis (p=0.2) and did not add power to the ColoPrint classification.

Risk assessment by ColoPrint in 97 patients with stage III colorectal cancer was not significantly correlated with the development of distant metastasis. Data were presented at the ASCO meeting in Chicago. ...